Statera Biopharma (STAB) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends STAB vs. CALA, EVLO, VAXX, SCPS, AMPE, CMRA, GNCA, ARDS, EFTR, and ONCSQShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Calithera Biosciences (CALA), Evelo Biosciences (EVLO), Vaxxinity (VAXX), Scopus BioPharma (SCPS), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), eFFECTOR Therapeutics (EFTR), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Calithera Biosciences Evelo Biosciences Vaxxinity Scopus BioPharma Ampio Pharmaceuticals Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals eFFECTOR Therapeutics OncoSec Medical Statera Biopharma (NASDAQ:STAB) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking. Which has higher valuation and earnings, STAB or CALA? Calithera Biosciences has higher revenue and earnings than Statera Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera Biopharma$1.49MN/A-$101.85MN/AN/ACalithera Biosciences$9.75M0.00-$39.65MN/AN/A Which has more risk & volatility, STAB or CALA? Statera Biopharma has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.09, indicating that its stock price is 209% less volatile than the S&P 500. Is STAB or CALA more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Calithera Biosciences N/A N/A N/A Does the MarketBeat Community prefer STAB or CALA? Calithera Biosciences received 341 more outperform votes than Statera Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformStatera BiopharmaN/AN/ACalithera BiosciencesOutperform Votes34157.21% Underperform Votes25542.79% Does the media prefer STAB or CALA? In the previous week, Calithera Biosciences had 1 more articles in the media than Statera Biopharma. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Statera Biopharma. Statera Biopharma's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score. Company Overall Sentiment Statera Biopharma Neutral Calithera Biosciences Neutral SummaryCalithera Biosciences beats Statera Biopharma on 4 of the 5 factors compared between the two stocks. Ad Resource Stock DigestThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best names in the lithium space will be set for escalating gains in 2025 and beyond. It’s all being driven by the global EV boom as millions of drivers ditch their gasoline-chugging cars and trucks in favor of lithium-ion-powered vehicles in record numbers. Everything you need to know is in our FREE online lithium report you can get here. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10,000.00$6.41B$4.99B$8.73BDividend YieldN/A8.11%5.18%4.07%P/E RatioN/A10.02131.5917.49Price / SalesN/A322.071,207.5889.33Price / CashN/A22.1633.2732.46Price / BookN/A5.504.684.66Net Income-$101.85M$152.72M$117.80M$224.87M7 Day PerformanceN/A-4.08%-2.38%-2.25%1 Month PerformanceN/A-8.51%-3.97%-0.19%1 Year PerformanceN/A29.22%29.85%24.36% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/AN/AN/AN/A$10,000.00$1.49M0.0020CALACalithera BiosciencesN/A$0.01flatN/A-76.0%$35,000.00$9.75M0.0060News CoverageEVLOEvelo BiosciencesN/A$0.00flatN/A-99.9%$28,000.00N/A0.00120News CoverageGap UpVAXXVaxxinityN/A$0.00flatN/A-100.0%$25,000.00$70,000.000.0090SCPSScopus BioPharmaN/A$0.00flatN/A-99.3%$13,000.00N/A0.009AMPEAmpio PharmaceuticalsN/A$0.01+∞N/A-99.9%$11,000.00N/A0.0020Gap DownCMRAComera Life SciencesN/A$0.00flatN/A-99.3%$9,000.00$630,000.000.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/AN/AN/AN/A$5,000.00$3.09M0.0030EFTReFFECTOR Therapeutics1.308 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010Negative NewsONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040 Related Companies and Tools Related Companies Calithera Biosciences Competitors Evelo Biosciences Competitors Vaxxinity Competitors Scopus BioPharma Competitors Ampio Pharmaceuticals Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors eFFECTOR Therapeutics Competitors OncoSec Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STAB) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored31 Billionaires Are Loading Up on This SectorWhy are 31 of the world's richest billionaires, like Warren Buffett, Jeff Bezos, the Walton family, and Bill G...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STAB Stock Alerts